n-methyl-3,4-methylenedioxyamphetamine has been researched along with dextromethorphan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Baggott, M; Heifets, B; Jones, RT; Mendelson, J; Sferios, E; Zehnder, J | 1 |
| Haining, RL; Ramamoorthy, Y; Sellers, EM; Suh, N; Tyndale, RF; Yu, AM | 1 |
| Arnold, DH | 1 |
| Commandeur, JN; de Graaf, C; Keizers, PH; Lussenburg, BM; Mentink, LM; Vermeulen, NP | 1 |
| Kennedy, CL; Parks, KA | 1 |
| Hargreaves, J; Heydari, A; Lennard, MS; Rostami-Hodjegan, A; Rowland-Yeo, K; Tucker, GT; Van, LM; Yang, J | 1 |
| Bonifacio, A; Commandeur, JN; Gooijer, C; Keizers, PH; Robert, B; van der Zwan, G; Vermeulen, NP | 1 |
| Commandeur, JN; Damsten, MC; Maasdijk, DM; van Vugt-Lussenburg, BM; Vermeulen, NP | 1 |
| Commandeur, JN; Lastdrager, J; Oostenbrink, C; Stjernschantz, E; van Vugt-Lussenburg, BM; Vermeulen, NP | 1 |
| Hammond, C; Hargreaves, JA; Rostami-Hodjegan, A; Swales, J; Van, LM; Wilson, C | 1 |
| Hargreaves, JA; Lennard, MS; Rostami-Hodjegan, A; Tucker, GT; Van, LM | 1 |
| Abanades, S; Cuyàs, E; de la Torre, R; Farré, M; Maluf, S; O'Mathúna, B; Pardo, R; Rostami-Hodjegan, A; Torrens, M; Tucker, GT; Yang, J | 1 |
| Dermatis, H; Franklin, J; Galanter, M; Horowitz, A | 1 |
| Carbó, ML; de la Torre, R; Farré, M; Mustata, C; O'Mahony, B; Pardo, R; Pérez-Mañá, C; Torrens, M; Yubero-Lahoz, S | 1 |
| Eggleston, W; Stork, C | 1 |
| Berretta, P; Busardò, FP; Gentili, S; Gregori, A; Pacifici, R; Pichini, S | 1 |
| Chang, KW; Chen, CF; Cheng, CY; Chueh, SH; Hsu, TH; Huang, WS; Huang, YS; Liao, MH; Liu, TT; Ma, KH; Sung, CC; Weng, SJ | 1 |
| Davydov, DR; Davydova, NY; Jones, JP; Paragas, EM; Rodgers, JT | 1 |
| Bates, MLS; Trujillo, KA | 1 |
2 review(s) available for n-methyl-3,4-methylenedioxyamphetamine and dextromethorphan
| Article | Year |
|---|---|
Generation Z: Adolescent Xenobiotic Abuse in the 21st Century.
Topics: Adolescent; Amphetamine-Related Disorders; Cannabinoids; Central Nervous System Stimulants; Designer Drugs; Dextroamphetamine; Dextromethorphan; Excitatory Amino Acid Antagonists; Hallucinogens; Humans; Inhalant Abuse; Ketamine; Methylphenidate; N-Methyl-3,4-methylenedioxyamphetamine; Phencyclidine Abuse; Receptors, N-Methyl-D-Aspartate; Substance-Related Disorders; Xenobiotics | 2015 |
Use and abuse of dissociative and psychedelic drugs in adolescence.
Topics: Adolescent; Adult; Age Factors; Animals; Dextromethorphan; Female; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Male; N-Methyl-3,4-methylenedioxyamphetamine; Phencyclidine; Psilocybin; Risk-Taking; Substance-Related Disorders | 2021 |
2 trial(s) available for n-methyl-3,4-methylenedioxyamphetamine and dextromethorphan
| Article | Year |
|---|---|
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
Topics: Adult; Area Under Curve; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Enzyme Inhibitors; Half-Life; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Phenotype; Pilot Projects; Time Factors | 2008 |
Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Dextromethorphan; Female; Genotype; Half-Life; Hallucinogens; Humans; Male; Models, Biological; N-Methyl-3,4-methylenedioxyamphetamine; Phenotype; Sex Factors; Spain; Substrate Specificity; Young Adult | 2011 |
15 other study(ies) available for n-methyl-3,4-methylenedioxyamphetamine and dextromethorphan
| Article | Year |
|---|---|
Chemical analysis of ecstasy pills.
Topics: Dextromethorphan; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Substance-Related Disorders; United States | 2000 |
Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Topics: Alleles; Cocaine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Drug Interactions; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Hallucinogens; Humans; In Vitro Techniques; Microsomes, Liver; N-Methyl-3,4-methylenedioxyamphetamine; Oxidation-Reduction; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors | 2002 |
Consultation with the specialist: the central serotonin syndrome: paradigm for psychotherapeutic misadventure.
Topics: Adolescent; Amphetamine-Related Disorders; Antidepressive Agents; Antitussive Agents; Anxiety Disorders; Child; Dextromethorphan; Diagnosis, Differential; Drug Interactions; Female; Fluvoxamine; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Obsessive-Compulsive Disorder; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Syndrome; Sertraline | 2002 |
Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Topics: Alanine; Coumarins; Cytochrome P-450 CYP2D6; Dextromethorphan; Humans; Models, Biological; Models, Molecular; Mutagenesis; N-Methyl-3,4-methylenedioxyamphetamine; Phenylalanine | 2004 |
Club drugs: reasons for and consequences of use.
Topics: Adolescent; Adult; Central Nervous System Stimulants; Dextromethorphan; Female; Flunitrazepam; Hallucinogens; Humans; Illicit Drugs; Interviews as Topic; Ketamine; Life Style; Lysergic Acid Diethylamide; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Sodium Oxybate; Substance-Related Disorders; United States | 2004 |
The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Topics: Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Data Interpretation, Statistical; Dextromethorphan; Dextrorphan; DNA, Complementary; Enzyme Inhibitors; Half-Life; Hallucinogens; Humans; Kinetics; Microsomes; N-Methyl-3,4-methylenedioxyamphetamine; Organisms, Genetically Modified; Saccharomyces cerevisiae; Spectrometry, Fluorescence | 2006 |
Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.
Topics: Amino Acid Substitution; Binding Sites; Cytochrome P-450 CYP2D6; Dextromethorphan; Ethanolamines; Heme; Humans; Mutation; N-Methyl-3,4-methylenedioxyamphetamine; Spectrum Analysis, Raman | 2006 |
Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3.
Topics: Acetaminophen; Amodiaquine; Arginine; Benzoflavones; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Activation; Humans; Kinetics; Leucine; Molecular Structure; Mutation; N-Methyl-3,4-methylenedioxyamphetamine; Pharmaceutical Preparations; Phenylalanine; Substrate Specificity | 2006 |
Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
Topics: Bacterial Proteins; Binding Sites; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Kinetics; Mixed Function Oxygenases; Models, Molecular; Mutagenesis; Mutation; N-Methyl-3,4-methylenedioxyamphetamine; NADPH-Ferrihemoprotein Reductase; Oxazines; Sequence Analysis, DNA | 2007 |
Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
Topics: Algorithms; Cell Count; Cell Survival; Cryopreservation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Enzyme Inhibitors; Enzyme Stability; Hepatocytes; Humans; Kinetics; N-Methyl-3,4-methylenedioxyamphetamine; Quinidine; Time Factors | 2007 |
Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Enzyme Inhibitors; Humans; Kinetics; Microsomes; N-Methyl-3,4-methylenedioxyamphetamine; Recombinant Proteins; Saccharomyces cerevisiae | 2007 |
Use of and attitudes toward club drugs by medical students.
Topics: Adult; Anesthetics, Intravenous; Anti-Anxiety Agents; Central Nervous System Stimulants; Dextromethorphan; Excitatory Amino Acid Antagonists; Female; Flunitrazepam; Hallucinogens; Health Knowledge, Attitudes, Practice; Humans; Illicit Drugs; Ketamine; Lysergic Acid Diethylamide; Male; Methamphetamine; Midwestern United States; N-Methyl-3,4-methylenedioxyamphetamine; Sex Distribution; Sodium Oxybate; Students, Medical; Substance-Related Disorders; Surveys and Questionnaires; Young Adult | 2008 |
Purity and adulterant analysis of some recent drug seizures in Italy.
Topics: Caffeine; Central Nervous System Depressants; Chromatography, Gas; Cocaine; Dextromethorphan; Drug Contamination; Hallucinogens; Heroin; Illicit Drugs; Italy; N-Methyl-3,4-methylenedioxyamphetamine; Narcotics | 2017 |
Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [
Topics: Animals; Brain; Cinanserin; Dextromethorphan; Iodine Radioisotopes; Magnetic Resonance Imaging; N-Methyl-3,4-methylenedioxyamphetamine; Primates; Serotonin; Time Factors; Tomography, Emission-Computed, Single-Photon | 2016 |
Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Gene Expression Regulation, Enzymologic; Humans; Kinetics; Molecular Structure; N-Methyl-3,4-methylenedioxyamphetamine; Serotonin Agents | 2018 |